These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36290810)

  • 1. Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice.
    Dri A; Garattini SK; Cinausero M; Macerelli M; Fanelli M; Puglisi F; Fasola G; Ermacora P
    Curr Oncol; 2022 Sep; 29(10):6776-6786. PubMed ID: 36290810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1225-1232. PubMed ID: 34167420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity Management of Systemic Kidney Cancer Therapies.
    Qin Q; Nein E; Flaten A; Zhang T
    Hematol Oncol Clin North Am; 2023 Oct; 37(5):993-1003. PubMed ID: 37353375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer.
    Zengin ZB; Salgia NJ; Chehrazi-Raffle A; Meza L; Malhotra J; Pal SK
    Cancer J; 2020; 26(5):432-440. PubMed ID: 32947311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma - A retrospective study.
    Jammal N; Pan E; Hurwitz M; Abramovitz RB
    J Oncol Pharm Pract; 2020 Apr; 26(3):556-563. PubMed ID: 31216241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
    Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
    Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
    [No Abstract]   [Full Text] [Related]  

  • 7. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
    de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
    Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
    Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
    Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Massari F
    Future Oncol; 2022 Feb; 18(5):625-634. PubMed ID: 34927453
    [No Abstract]   [Full Text] [Related]  

  • 11. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
    Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
    Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
    Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
    Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
    Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F
    Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
    Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
    J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.
    Roy AM; George S
    Immunotherapy; 2023 Apr; 15(6):397-400. PubMed ID: 36861344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
    Jaimes EA
    Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.
    Massari F; Nunno VD; Mollica V; Montironi R; Cheng L; Cimadamore A; Blanca A; Lopez-Beltran A
    Immunotherapy; 2019 Dec; 11(17):1507-1521. PubMed ID: 31663411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
    Gulati S; Vaishampayan U
    Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.